Showing results (41-50 of 168) with videos related to

Sort By:
Pageof 17
British Journal of Haematology|February 4, 2020
Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapyRory McCulloch, Carlo Visco, Toby A Eyre, et al.
Cancers|December 11, 2019
Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid LeukemiaPaul Takam Kamga, Giada Dal Collo, Federica Resci, et al.
Cytotherapy|July 8, 2020
A serum-free protocol for the ex vivo expansion of Cytokine-Induced Killer cells using gas-permeable static culture flasksPierangela Palmerini, Anna Dalla Pietà, Roberta Sommaggio, et al.
British Journal of Haematology|May 16, 2020
Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphomaFulvio Massaro, Yana Stepanishyna, Martina Manni, et al.
Cancers|January 20, 2021
Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell TherapyMiriam Marangon, Carlo Visco, Anna Maria Barbui, et al.
Cytotherapy|September 10, 2025
Overcoming barriers to referral for CAR T-cell therapy in patients with non-Hodgkin aggressive B-cell lymphomas: A Delphi consensusStefano Luminari, Annalisa Chiappella, Alice Di Rocco, et al.
Haematologica|September 22, 2011
Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomesEnrica Rampazzo, Laura Bonaldi, Livio Trentin, et al.
Leukemia & Lymphoma|November 28, 2017
Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendationsMartin Dreyling, Igor Aurer, Sergio Cortelazzo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2012
Immune thrombocytopenia in patients with chronic lymphocytic leukemia is associated with stereotyped B-cell receptorsCarlo Visco, Francesco Maura, Giacomo Tuana, et al.
BMC Cancer|August 25, 2025
The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatmentStephanie Herold, Christian Schmidt, Carlo Visco, et al.
Pageof 17